TDTuo Deng

Tuo Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tuo Deng has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Leqi Liang

    Department of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    8 shared publications
  • Shan Ao

    Department of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    8 shared publications
  • Xiaolu Duan

    Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province 510000, China

    8 shared publications
  • Guohua Zeng

    Department of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    7 shared publications
  • Zugen Chen

    Department of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    7 shared publications
  • Guohua Zeng

    Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    5 shared publications

Latest Publications

  • Open Access

    The dual tumor-suppressive mechanisms of STAM in clear cell renal cell carcinoma: EGFR inactivation and autophagy activation via AKT regulation

    by Zugen Chen, Leqi Liang, Lei Peng, Menghua Liao, Wenxia Lv, Shan Ao, Zikun Peng, Ming Lei, Di Gu, Yongda Liu, et al.

  • Open Access

    Identification and validation of an m5C-related lncRNA signature for predicting prognosis and immune response in clear cell renal cell carcinoma

    by Shan Ao, Leqi Liang, Lei Peng, Riwei Yang, Zugen Chen, Tuo Deng

    This study investigated whether m5C-related Long non-coding RNAs (lncRNAs) can predict clear cell renal cell carcinoma (ccRCC) patient prognosis. Co-expression and Cox regression analyses identified 9 prognostic lncRNAs, which were closely associated with tumor immune characteristics and immune escape. The model also predicted the sensitivity of drugs, including Entinostat, SB216763, and Sapitinib. In vitro experiments showed that GNG12-AS1 inhibited ccRCC cell proliferation and migration by reducing the activity of the ERK/GSK-3β/β-catenin pathway. Overall, these findings suggest that the 9 m5C-related lncRNAs can accurately predict ccRCC patient prognosis, providing potential applications for clinical and immunotherapy approaches. GNG12-AS1 emerges as a promising prognostic biomarker for predicting survival outcomes in ccRCC, potentially influencing cell migration through the activation of the ERK/GSK-3β/β-catenin signaling pathway.


  • Open Access

    Efficacy and safety of Le Fort colpocleisis in the treatment of stage III-IV pelvic organ prolapse

    by Leqi Liang, Shan Ao, Su Wang, Zugen Chen, Lei Peng, Liquan Chen, Lizhen Xu, Xiaowei Zhang, Tuo Deng

    Le Fort colpocleisis is an obliterative surgery for the treatment of pelvic organ prolapse (POP). In this study, we aimed to investigate the efficacy and safety of Le Fort colpocleisis in the treatment of patients with stage III-IV POP. The study was designed as a retrospective analysis of a single-center case series. Patients with stage III-IV POP treated with Le Fort colpocleisis were included. Perioperative indicators, subjective and objective outcomes and complications were assessed. The POP-Quantification (POP-Q) system was used for objective outcome evaluation. Pelvic Floor Distress Questionnaire (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) were used for subjective outcome evaluation. A total of 54 patients with complete pre- and postoperative data completed follow-up and were included in our study. The mean Âħ standard deviation of operative time, intraoperative blood loss, recovery activity time, postoperative hospitalization time and total hospitalization time were 146.85 Âħ 37.01 min, 92.04 Âħ 68.31 ml, 2.81 Âħ 0.85 days, 6.5 Âħ 2.11 days and 13.52 Âħ 4.78 days, respectively. Within the median follow-up period of 38.5 months, the objective cure rate of Le Fort colpocleisis reached 98.15% (53/54), and the subjective cure rate reached 92.59% (50/54). No serious complications were reported during the perioperative period and follow-up period. Le Fort colpocleisis is an effective and safe procedure for the treatment of severe POP. Because of its lower operative risk, better subjective and objective outcomes, lower rates of prolapse recurrence and perioperative complications, Le Fort colpocleisis should be considered as the recommended procedure for elderly patients with severe POP (stage III-IV).


  • Open Access

    Terminal Unfolded Protein Responses-related genes predict prognosis and associate with proliferation and apoptosis in clear cell renal cell carcinoma

    by Riwei Yang, Leqi Liang, Shan Ao, Zugen Chen, Zude Chen, Tuo Deng

    Background Terminal unfolded protein response (TUPR), a self-destruct mechanism of cells, initiates when irreversible endoplasmic reticulum stress (ER stress) occurs and causes cell apoptosis. Current studies show that TUPR also leads to apoptosis in carcinoma, which plays an indispensable role in development of tumors. However, understanding the specific role of TUPR in ccRCC cells is important for the treatment of tumors. Methods Based on 9 TUPR-associated genes, clusters of ccRCC patients were identified by unsupervised clustering. Prognostic models were constructed by LASSO regression and multivariate cox regression. Tunicamycin (Tm) was used to induce TUPR in ccRCC cells, and gene expression, proliferation, and apoptosis of ccRCC cells under TUPR were investigated by RT-qPCR, EdU and immunofluorescence staining respectively. Results ccRCC patients were distinguished into two clusters with various signatures. We confirmed that the TUPR-related prognostic model had a good predictive ability. 12 hours-Tm treatment induced TUPR in ccRCC cells and inhibited cell proliferation and promoted apoptosis. Silencing STT3B increased the sensitivity, inhibited the proliferation and promoted the apoptosis of ccRCC cells. Conclusion TUPR-associated genes were significantly correlated with clinical features of ccRCC patients, and were involved in ccRCC proliferation and apoptosis, which may become a new treatment option. STT3B may serve as a promising ccRCC therapeutic target.

  • LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma

    by Riwei Yang, Zude Chen, Shan Ao, Leqi Liang, Zugen Chen, Xiaolu Duan, Guohua Zeng, Tuo Deng


  • Open Access

    Identification and Validation of a m5c-related lncrna signature predict prognosis and immune response of clear cell renal cell carcinoma

    by Shan Ao, Leqi Liang, Riwei Yang, Zugen Chen, Lei Peng, Tuo Deng

    Objective M5C-related LncRNAs (Long non-coding RNAs) were related to the occurrence and development of tumors. In this study, we investigated whether m5C-related LncRNAs could predict the prognosis of clear cell renal cell carcinoma (ccRCC) patients. Methods Co-expression analysis and Cox regression analysis were used to construct prognostic features, and then a series of model validation was performed to evaluate the prognostic value of the model. Gene Ontology (GO), Kyoto Encyclopedia of Gene and Genome Enrichment (KEGG), immune-related function and tumor mutation burden (TMB) analyses were also performed. Finally, the potential sensitivity of drugs to ccRCC was predicted. Results A total of 9 m5C-related LncRNAs were obtained and a prognostic model was established. Our model has independent prognostic value and is closely related to tumor immune characteristics and immune escape, which can be used to predict the sensitivity of drugs including Entinostat, SB216763, and Sapitinib. Our in vitro experiments showed that GNG12-AS1 inhibited cell proliferation and migration in ccRCC cell lines. Conclusions In summary, the 9 m5C-related LncRNAs can accurately predict the prognosis of ccRCC patients, which may provide new ideas for clinical application and immunotherapy of ccRCC patients, and GNG12-AS1 is a promising prognostic biomarker for predicting survival outcome of ccRCC.

  • Open Access

    LncRNA MAGI2-AS3 inhibited tumour progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma

    by Riwei Yang, Zude Chen, Shan Ao, Leqi Liang, Zugen Chen, Xiaolu Duan, Guohua Zeng, Tuo Deng

    Background: Non-coding RNA (ncRNA) is a class of RNAs that do not encode proteins but have multiple biological functions intracellular. They play an indispensable role in the occurrence and development of tumour. Therefore, understanding their molecular regulatory mechanisms in tumour cells are important for the treatment of tumour patients. Methods: The upstream ncRNAs of STAM were predicted by bioinformatic analysis, and the specific mechanism of lncRNA MAGI2-AS3 regulated miR-142-3p affecting STAM expression and participating in ccRCC cell proliferation, invasion, migration and apoptosis was detected by RT-qPCR, Western blotting, cellular functional experiments and luciferase reporter assay. Results: Overexpression of miR-142-3p or silencing of MAGI2-AS3 promoted the proliferation and migration of ccRCC cells, and inhibits cell apoptosis, while silencing of miR-142-3p or overexpression of MAGI2-AS3 had the opposite effect on ccRCC cells. Furthermore, we confirmed that MAGI2-AS3 acted as sponge and combined with miR-142-3p, blocked the inhibitory effect of miR-142-3p on the expression of STAM, thereby involved in ccRCC proliferation and metastasis. Furthermore, the prognostic model based on the MAGI2-AS3/miR-142-3p/STAM axis further emphasizes its prognostic value in ccRCC. Conclusion: MAGI2-AS3 competitively binding miR-142-3p to upregulate the STAM expression suppressing ccRCC proliferation and metastasis. MAGI2-AS3/miR-142-3p/STAM axis may serve as a promising ccRCC therapeutic target.

  • PET Imaging of Bromodomain and Extra-Terminal Domain Inhibitors for the Noninvasive Assessment of Metabolic Changes in the Liver and Brain of Early-Stage Alcoholic Liver Disease

    by Zude Chen, Riwei Yang, Yulong Xu, Leqi Liang, Shan Ao, Zuomin Wang, Ping Bai, Di Gu, Xiaolu Duan, Yongda Liu, et al.

    Alcoholic liver disease (ALD) has a significant impact on human health and is one of the leading causes of liver disease mortality. The early and exact diagnosis of ALD is very important since the early stage of disease progression can be reversible. Although ALD can be evaluated by ultrasound, CT, or MRI, there is still no imaging technique sufficient in the diagnosis of early-stage ALD. Of the current studies, epigenetic modulation plays a significant role in the development and progression of ALD. In this work, we evaluate whether BRDs play a vital role in the early-stage ALD using our new PET imaging probe of BET proteins, [C-11]CW22. PET/CT imaging of [C-11]CW22 and [F-18]FDG was used to identify early-stage lesions of livers and brains in the mice model. We found that the average uptake values of livers and brains in early-stage ALD were significantly increased for [C-11]CW22 PET/CT imaging but only slightly changed in [F-18]FDG PET/CT imaging. Consistently, we also found that BRD 3, 4 protein expression levels were significantly higher in the liver and brain tissues of early-stage ALD. Furthermore, through Pmod software, we found that [C-11]CW22 PET/CT uptakes in the brain stem, cerebellum, and midbrain were significantly up-regulated in the early-stage ALD. In conclusion, BRDs were important mediators of damage in early-stage ALD. [C-11]CW22 PET/CT imaging can detect the early-phase alcohol-induced damage of livers and brains, which will likely lead to human trials in the future.


  • Open Access

    Risk Factors for Non-arteritic Anterior Ischemic Optic Neuropathy: A Large Scale Meta-Analysis

    by Bing Liu, Ying Yu, Wen Liu, Tuo Deng, Daoman Xiang

    Objective: We conducted a meta-analysis to explore all the potential risk factors for non-arteritic anterior ischemic optic neuropathy (NAION) based on the published literature.Methods: A comprehensive literature search through the online databases was performed to obtain studies concerning the risk factors of NAION up to June 2020. Pooled unadjusted odds ratios (ORs) or rate ratios (RRs) were calculated to evaluate the weight of risk factors. This study was registered in PROSPERO under the number CRD42018084960.Results: Our meta-analysis included 49 original studies comprising of more than 10 million patients. The following risk factors were proved to be significantly associated with NAION: male gender (OR = 1.67, 95% CI: 1.50–1.85, P < 0.00001), hypertension (RR = 1.28, 95% CI: 1.20–1.37, P < 0.00001), hyperlipidemia (RR = 1.43, 95% CI: 1.26–1.62, P < 0.00001), diabetes mellitus (DM) (RR = 1.53, 95% CI: 1.36–1.73, P < 0.00001), coronary heart disease (CHD) (RR = 1.68, 95% CI: 1.24–2.27, P = 0.0008), sleep apnea (RR = 3.28, 95% CI: 2.08–5.17, P < 0.00001), factor V Leiden heterozygous (RR = 2.21, 95% CI: 1.19–4.09, P = 0.01), and medication history of cardiovascular drugs.Conclusion: We concluded that the above risk factors were significantly related to NAION. Better understanding of these risk factors in NAION can help the direct therapeutic approaches.


  • Open Access

    Corrigendum: STAM Prolongs Clear Cell Renal Cell Carcinoma Patients’ Survival via Inhibiting Cell Growth and Invasion

    by Tuo Deng, Zihao He, Xiaolu Duan, Di Gu, Chao Cai, Wenqi Wu, Yongda Liu, Guohua Zeng

    Corrigendum: STAM Prolongs Clear Cell Renal Cell Carcinoma Patients’ Survival via Inhibiting Cell Growth and Invasion